Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma

Leukemia. 2019 Oct;33(10):2540-2544. doi: 10.1038/s41375-019-0476-y. Epub 2019 May 21.

Tania Jain¹, Craig S Sauter^{1

2}, Gunjan L Shah^{1

2}, Molly A Maloy¹, Jason Chan¹, Michael Scordo^{1

2}, Scott T Avecilla³, Yakup Batlevi¹, Parastoo B Dahi^{1

2}, Connie W Batlevi^{2

4}, M Lia Palomba^{2

4}, Sergio A Giralt^{1

2}, Miguel-Angel Perales^{5

6}

¹ Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
² Department of Medicine, Weill Cornell Medical College, New York, NY, 10021, USA.
³ Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
⁴ Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
⁵ Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. peralesm@MSKCC.ORG.
⁶ Department of Medicine, Weill Cornell Medical College, New York, NY, 10021, USA. peralesm@MSKCC.ORG.

No abstract available

Publication types